Shots: GI to receive up front, milestones, and royalties on sales in China, including mainland China, Hong Kong, Macau, and Taiwan while Simcere will be responsible for all clinical development, […]readmore
Tags : Simcere
1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: Incyte, Reports, Updated, Results, Pemigatinib, P-II, FIGHT-202 […]readmore
Shots: JWP to receive up front, commercial milestones & royalties on sales in China. Simcere to get the license for clinical research, registration, and commercialization of URC-102 in China (including […]readmore